Avacta Group completed the acquisition of Coris Bioconcept for £10m.

Avacta Group, a life science company developing innovative, targeted oncology drugs and powerful diagnostics, completed the acquisition of Coris Bioconcept, a manufacturer of diagnostic test kits, mainly lateral flow tests, for use by healthcare professionals for £10m. "The acquisition of Coris provides the Group with a broad, professional-use rapid test product portfolio. Complementing the acquisition of Launch Diagnostics last year, the Acquisition represents an important step in establishing a full-spectrum in-vitro diagnostics business covering centralised, pathology laboratory diagnostics, as well as decentralised, point-of-care testing solutions outside the hospital setting." Alastair Smith, Avacta Group Chief Executive Officer.